This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
Cancer immunotherapy has transformed treatment for several advanced cancers, yet the difference between these treatments working and not could depend on simple routine habits. A recent study published in Science Signaling explores one such overlooked factor: regular alcohol consumption.
The focus was on immune checkpoint inhibitors (ICIs), a class of drugs that includes anti-programmed cell death protein 1 (PD-1) therapies that train the body's immune system to attack tumor cells. The researchers used a mouse model and human clinical data to investigate how regular alcohol consumption impacts the success of ICIs.
The effects were evident in both animal models and human patients. In mice with lung and bladder cancer, moderate-to-heavy alcohol consumption cut the success of immunotherapy by nearly half and increased the likelihood of tumors returning. A similar pattern emerged in human clinical data, where lung cancer patients who regularly consumed alcohol, more than one drink a week, experienced fewer survival benefits after starting anti-PD-1 treatment.
The body's immune system relies on specialized white blood cells called T cells to seek out and destroy cancer cells. To prevent these immune cells from becoming overactive and attacking healthy tissues, T cells have natural off-switches, including a receptor protein called programmed cell death protein 1 (PD-1).
Cancer cells can hijack this mechanism by activating the PD-1 off-switch on T cells, effectively putting the brakes on the immune system and allowing tumors to escape attack.
Source link







